ARID1B and non-small cell lung carcinoma: Knocking out ARID1B enhanced the susceptibility of two subtypes of non-small cell lung cancer cells to T cell-mediated cytotoxicity (Fig. 5B), and knocking out ARID1B increased the number of lung cancer cells dying when co cultured with T cells in both subtypes of non-small cell lung cancer.